Brief: Soligenix Submits Type A Meeting Request To U.S. FDA

Soligenix

24/04/2023 12:45

April 24 (Reuters) - Soligenix Inc  SNGX.O :
    * SOLIGENIX SUBMITS TYPE A MEETING REQUEST TO U.S. FDA TO
REVIEW
PROPOSED STUDY DESIGN FOR A SECOND PHASE 3 STUDY EVALUATING
HYBRYTE™ IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA
    * SOLIGENIX INC - MEETING EXPECTED TO OCCUR APPROXIMATELY 30
DAYS
FROM FDA'S RECEIPT OF MEETING REQUEST

Source text for Eikon:  ID:nPnJQxdKa 
Further company coverage:  SNGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))